| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
AGL Stock Overview
ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products.
ANGLE plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.72 |
| 52 Week High | UK£1.64 |
| 52 Week Low | UK£0.67 |
| Beta | 0.84 |
| 1 Month Change | -28.36% |
| 3 Month Change | -33.02% |
| 1 Year Change | -32.07% |
| 3 Year Change | -4.64% |
| 5 Year Change | 58.94% |
| Change since IPO | -51.84% |
Recent News & Updates
ANGLE (LON:AGL) Is In A Good Position To Deliver On Growth Plans
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Shareholder Returns
| AGL | GB Medical Equipment | GB Market | |
|---|---|---|---|
| 7D | -5.3% | 4.4% | 0.8% |
| 1Y | -32.1% | -17.7% | -6.4% |
Return vs Industry: AGL underperformed the UK Medical Equipment industry which returned -17.9% over the past year.
Return vs Market: AGL underperformed the UK Market which returned -6.8% over the past year.
Price Volatility
| AGL volatility | |
|---|---|
| AGL Average Weekly Movement | 19.2% |
| Medical Equipment Industry Average Movement | 5.8% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in GB Market | 10.8% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: AGL is more volatile than 90% of UK stocks over the past 3 months, typically moving +/- 19% a week.
Volatility Over Time: AGL's weekly volatility has increased from 12% to 19% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 128 | Andrew David Newland | https://angleplc.com |
ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products. The company develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor cells in metastatic breast cancer patient blood; and HyCEAD multiplex analysis system for routine and focused multiplex analysis of DNA, RNA or protein biomarkers. The company was founded in 1994 and is based in Guildford, the United Kingdom.
ANGLE plc Fundamentals Summary
| AGL fundamental statistics | |
|---|---|
| Market Cap | UK£187.47m |
| Earnings (TTM) | -UK£15.01m |
| Revenue (TTM) | UK£1.01m |
185.1x
P/S Ratio-12.5x
P/E RatioIs AGL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AGL income statement (TTM) | |
|---|---|
| Revenue | UK£1.01m |
| Cost of Revenue | UK£959.00k |
| Gross Profit | UK£54.00k |
| Other Expenses | UK£15.07m |
| Earnings | -UK£15.01m |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
Sep 30, 2022
| Earnings per share (EPS) | -0.058 |
| Gross Margin | 5.33% |
| Net Profit Margin | -1,481.93% |
| Debt/Equity Ratio | 0% |
How did AGL perform over the long term?
See historical performance and comparison